Modulation of release from dry powder formulations
AssigneeAdvanced Inhalation Research, Inc.
InventorsSujit K. Basu, Jeffrey S. Hrkach, Giovanni Caponetti, Michael M. Lipp, Katharina Elbert, Wen-I Li
Life of this patent
Estimating the term…
Abstract
Particles which include a bioactive agent are prepared to have a desired matrix transition temperature. Delivery of the particles via the pulmonary system results in modulation of drug release from the particles. Sustained release of the drug can be obtained by forming particles which have a high matrix transition temperature, while fast release can be obtained by forming particles which have a low matrix transition temperature. Preferred particles include one or more phospholipids.
Claims40
Particles for modulation of drug release comprising:
- (a) a bioactive agent;
- and
- (b) a phospholipid or a combination of phospholipids, said phospholipid or combination of phospholipids, said particles having in a matrix transition temperature corresponding to a targeted release rate of the biologically active agent from the particles and a tap density of less than about 0.4 g/cm3.
A method for delivery via the pulmonary system comprising administering to the respiratory tract of a patient in need of treatment, prophylaxis or diagnosis an effective amount of particles having a selected release rate of a bioactive agent, said particles comprising:
- (a) the bioactive agent;
- and
- (b) a phospholipid or a combination of phospholipids, said phospholipid or combination of phospholipids;
- wherein the particles have a matrix transition temperature corresponding to a targeted release rate of the therapeutic, prophylactic or diagnostic agent from the particles and a tap density of less than about 0.4 g/cm3.
A method for delivery via the pulmonary system particles having a release rate from the particles of a therapeutic, prophylactic or diagnostic agent comprising:
- administering to the respiratory system of a patient in need of treatment, prophylaxis or diagnosis an effective amount of particles comprising:
- (a) the therapeutic, prophylactic or diagnostic agent, or combinations thereof;
- and
- (b) a phospholipid or a combination of phospholipids, said phospholipid or combination of phospholipids resulting in a matrix transition temperature such that the particles have the release rate;
- wherein the particles have a tap density less than about 0.4 g/cm3.
A method for increasing a release time of a therapeutic, prophylactic or diagnostic agent comprising administering to a patient in need of treatment, prophylaxis or diagnosis an effective amount of particles comprising:
- (a) a therapeutic, prophylactic or diagnostic agent;
- and
- (b) a phospholipid or a combination of phospholipids, said phospholipid or combination of phospholipids;
- wherein the particles have a transition temperature higher than the physiological temperature of the patient and a tap density of less than about 0.4 g/cm3.
Particles for modulation of drug release having a tap density of less than about 0.4 g/cm3 comprising:
- (a) a therapeutic, prophylactic or diagnostic agent;
- and
- (b) a phospholipid or combination of phospholipids, said phospholipid or combination of phospholipids having a transition temperature higher than the body temperature of a human or veterinary subject.
Dependencies are inferred from the claim text.